Selecta Biosciences, Inc., a Watertown, Mass.-based biopharmaceutical company developing a new class of targeted vaccines and immunotherapies, has raised $47.25m in new funding.
RUSNANO, additional new investors, and all of its existing investors participated in Selecta’s $22m Series D round. In addition, the company has raised additional funding up to $25.25m for strategic activities in Russia.
Selecta Biosciences intends to use the funding to broaden its research and development (R&D) capabilities by establishing a wholly-owned subsidiary in Moscow, Russia, and advance its new class of vaccines and immunotherapies.
Led by President and CEO Werner Cautreels, PhD, the company is developing a new class of vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications through its Synthetic Vaccine Particle (SVP™) platform.